1
00:00:02,000 --> 00:00:07,480
Survodutide brings GLP-1 and glucagon receptor activity into

2
00:00:07,480 --> 00:00:09,160
one peptide.

3
00:00:09,620 --> 00:00:12,820
Researchers are testing this combination for obesity and

4
00:00:12,820 --> 00:00:14,140
metabolic liver disease.

5
00:00:15,200 --> 00:00:19,540
It emerged from Boehringer Ingelheim and Zealand Pharma's partnership.

6
00:00:20,480 --> 00:00:24,220
Boehringer now leads global development, linking German and

7
00:00:24,220 --> 00:00:25,220
Danish research.

8
00:00:25,220 --> 00:00:30,820
A phase-three trial followed 725 adults without diabetes

9
00:00:30,820 --> 00:00:33,020
for 76 weeks.

10
00:00:33,620 --> 00:00:38,200
Average weight reductions were 12.2 and 13 percent,

11
00:00:38,500 --> 00:00:41,100
versus 5.4 percent with placebo.

12
00:00:41,810 --> 00:00:44,610
Body weight does not directly measure liver fat.

13
00:00:45,320 --> 00:00:49,800
Separate liver research used magnetic resonance imaging to measure fat.

14
00:00:50,700 --> 00:00:54,840
Lee Kaplan and colleagues treated 216 adults with

15
00:00:54,840 --> 00:00:58,120
obesity and at risk fatty liver disease.

16
00:00:58,120 --> 00:01:03,280
At 48 weeks, 68.5 percent reached at least

17
00:01:03,280 --> 00:01:06,520
a 30 percent relative liver fat reduction, versus

18
00:01:06,520 --> 00:01:09,240
28.6 percent with placebo.

19
00:01:10,500 --> 00:01:14,000
These analyses include treatment discontinuation.

20
00:01:14,360 --> 00:01:17,560
Tolerability can affect whether people continue treatment.

21
00:01:17,920 --> 00:01:22,380
Gastrointestinal symptoms were common and sometimes led to treatment stopping.

22
00:01:23,420 --> 00:01:26,620
Less liver fat does not by itself prove

23
00:01:26,620 --> 00:01:28,340
reversal of fibrosis.

24
00:01:28,340 --> 00:01:34,480
At the October 14, 2026 cutoff, survodutide remains

25
00:01:34,480 --> 00:01:35,720
investigational.

26
00:01:36,580 --> 00:01:40,940
Longer-term studies must establish lasting benefits and risks.

27
00:01:41,000 --> 00:01:44,480
Weight and liver-fat measurements are part of the evidence.

28
00:01:44,970 --> 00:01:48,430
Lasting health benefits remain the key question.

29
00:01:48,780 --> 00:01:50,050
Peptides in 2.

30
00:01:50,450 --> 00:01:52,230
World Peptide Foundation.

31
00:01:52,580 --> 00:01:54,940
Every experience matters.